Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2008 1
2016 1
2017 2
2020 2
2021 2
2022 1
2023 1
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis.
Parodis I, Lindblom J, Toro-Domínguez D, Beretta L, Borghi MO, Castillo J, Carnero-Montoro E, Enman Y, Mohan C, Alarcón-Riquelme ME, Barturen G, Nikolopoulos D; PRECISESADS Clinical Consortium. Parodis I, et al. Kidney Int Rep. 2024 Mar 13;9(6):1817-1835. doi: 10.1016/j.ekir.2024.03.014. eCollection 2024 Jun. Kidney Int Rep. 2024. PMID: 38899167 Free PMC article.
Molecular subtypes explain lupus epigenomic heterogeneity unveiling new regulatory genetic risk variants.
Castellini-Pérez O, Povedano E, Barturen G, Martínez-Bueno M, Iakovliev A, Kerick M, López-Domínguez R, Marañón C, Martín J, Ballestar E; PRECISEADS Clinical Consortium; PRECISEADS Flow Cytometry Study Group; Borghi MO, Qiu W, Zhu C, Shankara S, Spiliopoulou A, de Rinaldis E, Carnero-Montoro E, Alarcón-Riquelme ME. Castellini-Pérez O, et al. NPJ Genom Med. 2024 Jul 16;9(1):38. doi: 10.1038/s41525-024-00420-0. NPJ Genom Med. 2024. PMID: 39013887 Free PMC article.
Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
Lindblom J, Lagutkin D, Sherina N, Idborg H, Beretta L, Borghi MO; PRECISESADS Clinical Consortium; Peyper JM, Barturen G, Jakobsson PJ, Alarcón-Riquelme ME, Nikolopoulos D, Parodis I. Lindblom J, et al. Ann Rheum Dis. 2025 Jul;84(7):1164-1179. doi: 10.1016/j.ard.2025.04.008. Epub 2025 May 9. Ann Rheum Dis. 2025. PMID: 40348637 Free article.
Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
Parodis I, Lindblom J, Barturen G, Ortega-Castro R, Cervera R, Pers JO, Genre F, Hiepe F, Gerosa M, Kovács L, De Langhe E, Piantoni S, Stummvoll G, Vasconcelos C, Vigone B, Witte T; PRECISESADS Clinical Consortium; Alarcón-Riquelme ME, Beretta L. Parodis I, et al. Ann Rheum Dis. 2024 Jun 12;83(7):889-900. doi: 10.1136/ard-2023-224795. Ann Rheum Dis. 2024. PMID: 38373843 Free PMC article.
Dysregulation of innate and adaptive lymphoid immunity may have implications for symptom attribution and predict responses to targeted therapies in neuropsychiatric systemic lupus erythematosus.
Lindblom J, Barturen G, Beretta L, Toro-Domínguez D, Carnero-Montoro E, Borghi MO, Castillo J, Iacobaeus E, Enman Y; PRECISESADS Clinical Consortium; Mohan C, Alarcón-Riquelme ME, Nikolopoulos D, Parodis I. Lindblom J, et al. J Transl Autoimmun. 2025 Jun 11;11:100296. doi: 10.1016/j.jtauto.2025.100296. eCollection 2025 Dec. J Transl Autoimmun. 2025. PMID: 40672966 Free PMC article.
15 results